A phase 2 study of RTN-001 in patients with hypertension uncontrolled on two or more antihypertensives
Latest Information Update: 26 Aug 2024
At a glance
- Drugs RTN 001 (Primary)
- Indications Hypertension
- Focus Therapeutic Use
Most Recent Events
- 26 Aug 2024 New trial record
- 21 Aug 2024 According to a Retension Pharmaceuticals media release, company announced the successful closing of its Series A $10.4 million financing round to initiate a well-powered and controlled Phase 2 clinical study in patients with hypertension uncontrolled on two or more antihypertensives.